JAK Janus Kinase
(Unterschied zwischen Versionen)
| Zeile 1: | Zeile 1: | ||
| + | |||
| + | {{tp|p=32278797|t=ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2 |pdf=|usr=}} | ||
| + | {{tp|p=32339701|t=ä. Potential role of Janus kinase inhibitors in COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=32344070|t=ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19 |pdf=|usr=}} | ||
| + | |||
| + | |||
'''Tofacitinib''' | '''Tofacitinib''' | ||
Version vom 18. Juni 2020, 10:42 Uhr
32278797 ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2
32339701 ä. Potential role of Janus kinase inhibitors in COVID-19
32344070 ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19
Tofacitinib
32342098 ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib
Baricitinnib
32259575 ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19
